英文药名：ATROPINE SULFATE Injection（Atropine Sulfate Hydrate）

中文药名：硫酸阿托品注射剂

生产厂家：田边三菱制药
药品介绍
一般名：アトロピン硫酸塩水和物
一般名：（欧名） Atropine Sulfate Hydrate
化学名：(1R,3r,5S)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl[(RS)-3-hydroxy-2-phenyl]propanoate hemisulfate hemihydrate
分子式：(C17H23NO3)2・H2SO4・H2O
分子量：694.83
融点： 188〜194℃（分解）
化学结构式：

 
性状 
无色结晶或白色结晶性粉末，无臭。
非常易溶于水或乙酸（100），乙醇（95）它是易溶的，并且在乙醚中几乎不溶。
改变了光。
药理毒理
本品为典型的M胆碱受体阻滞剂。除一般的抗M胆碱作用解除胃肠平滑肌痉挛、抑制腺体分泌、扩大瞳孔、升高眼压、视力调节麻痹、心率加快、支气管扩张等外，大剂量时能作用于血管平滑肌，扩张血管、解除痉挛性收缩，改善微循环。此外本品能兴奋或抑制中枢神经系统，具有一定的剂量依赖性。对心脏、肠和支气管平滑肌作用比其他颠茄生物碱更强而持久
适应症
分泌和多动胃和十二指肠溃疡，胃肠痉挛性疼痛，痉挛性便秘，绞痛胆道和泌尿道，有机磷杀虫剂副交感神经兴奋剂中毒，迷走神经性心动过缓和迷走神经流苏房传导障碍，其他的心动过缓和房室传导障碍，术前的麻醉，ECT的管理
用法用量
阿托品硫酸盐水合物，成人注入正常0.5mg的（1管），以皮下或肌肉内。也可以通过静脉注射。
此外，增加或减少取决于患者的年龄和症状。
使用的症状以下面的方式
轻症
皮下注射0.5〜1mg的在（1-2管），或口服0.5〜1mg。
中等症
注入1〜2毫克的（2-4管）皮下，肌内或静脉注射。如果有必要，再重复将被注入每20至30分钟。
重症
首先，如注入2〜4mg的一个（4至8管）静脉内，重复注射，直至阿托品饱和迹象响应于随后的症状观察。
硫酸阿托品水合物，一般成人一次0.5毫克（1管）的皮下，肌注或静脉注射的情况下。
此外，想增加或减少取决于患者的年龄和症状。
包装规格：
硫酸阿托品0.5mg[田边]
1mL×10管，1mL×50管

生产商
田辺三菱製薬

完整资料附件：
http://www.kegg.jp/medicus-bin/japic_med?japic_code=00053655
Atropine Sulfate Dosage and Administration
Atropine Sulfate Injection, USP in the Ansyr Syringe is intended for intravenous use, but may be administered subcutaneously or intramuscularly. Its use usually requires titration, using heart rate, PR interval, blood pressure and/or patient’s symptoms as a guide for having reached an appropriate dose.
Adults
Initial single doses in adults vary from around 0.5 mg to 1 mg (5-10 mL of the 0.1 mg/mL solution for antisialagogue and other antivagal effects, to 2 to 3 mg (20-30 mL) of the 0.1 mg/mL solution) as an antidote for organophosporous or muscarinic mushroom poisoning. When used as an antidote, the 2 to 3 mg dose should be repeated no less often than every 20 to 30 minutes until the signs of poisoning are sufficiently lessened or signs of atropine poisoning (see ADVERSE REACTIONS and OVERDOSAGE) occur.
When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand. For patients with bradyasystolic cardiac arrest, a 1 mg dose of atropine is administered intravenously and is repeated every 3-5 minutes if asystole persists. Three milligrams (0.04 mg/kg) given I.V. is a fully vagolytic dose in most patients. The administration of this dose of atropine should be reserved for patients with bradyasystolic cardiac arrest. Administration of less than 0.5 mg can produce a paradoxical bradycardia because of the central or peripheral parasympathomimetic effects of low doses in adults.
Endotracheal administration of atropine can be used in patients without I.V. access. The recommended adult dose of atropine for endotracheal administration is 1 to 2 mg diluted to a total not to exceed 10 mL of sterile water or normal saline.
Titration intervals of one or two hours are recommended in circumstances that are not life-threatening.
Pediatrics
Dosing information in pediatric populations has not been well studied. Usage history of initial dose has been in the range of 0.01 to 0.03 mg/kg body weight.
Parenteral drug products should be inspected visually for particulate matter and/or discoloration prior to administration (see PRECAUTIONS).